The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.

Improving Outcomes in Vascular Disease – Aortic Dissection

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction

AOA DX is developing a blood test to detect ovarian cancer (biomarker).  The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop the ovarian cancer test.

The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL).

The purpose of this study is to evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy.

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).